The Novo Nordisk, Inc. (NNI) Investigator-Sponsored Studies (ISS) Program is dedicated to building on our 100-year heritage of putting patients first. The ISS Program supports independent, scientific investigations that add knowledge about our products and/or therapeutic areas of interest to improve patient outcomes. Our program seeks to enable high-quality, independent research that addresses evidence gaps, unmet needs, and potential areas of innovation.

Are you located outside the US? Please follow this link to see relevant information in regards to ISS applications outside US territory - Investigator Sponsored Studies Program outside US.

Deadline: July 15, 2026 at 11:59pm ET

Study drugs available for this submission window:

  • Cagrilintide 2.4mg-Semaglutide 2.4mg s.c. - Available: open-label-no placebo; blinded with matched placebo; Semaglutide monotherapy (and/or semaglutide matched placebo) can be requested in conjunction with cagrilintide-semaglutide (and/or matched placebo). No cagrilintide monotherapy is available.
  • Denecimig
  • Insulin Icodec
  • Semaglutide 7.2mg s.c. (matched placebo available)
  • Oral semaglutide 25mg (no matched placebo)

Review the following prior to submitting:

  • Areas of Interest
  • Submission information
  • Frequently asked questions
  • Materials in Help Section in online ISS portal (inRich)

Non-interventional, observational study design submissions are also accepted.

There are two annual submission deadlines: March 1 and October 1 at 11:59pm ET

Interventional drug research which processes data derived from humans or human specimens. Study drug must be provided by NNI.

Research measured according to standard of care, without any attempt to change or intervene. Data can be obtained through secondary use of data (e.g., claims data, medical chart review, electronic healthcare records, meta-analyses, etc.). 

Create an account on the ISS Portal. Refer to our ISS Portal Quick Reference Guide for instructions on how to navigate the system. 

Submission requirements include:

  • A well-written protocol and detailed line-item budget (e.g., when requesting funding) utilizing the NNI protocol and line-item budget templates. All budgets will be subject to Fair Market Value (FMV) analysis.
  • Investigator Curriculum Vitae (signed and dated within the last year)
  • Active medical license (e.g., if requesting study drug) is required of PI or co-PI
  • Conflict of Interest form


For more details about what is required for submission and how to access the protocol and line-item budget templates, refer to our Quick Reference Guide and our ISS Portal Quick Reference Guide. 

All applications are reviewed through a multi-phased process. Relevant Novo Nordisk reviewers may include Medical Clinical & Regulatory Affairs, Product Safety, Health Economics and Outcomes research specialists, etc.

The ISS Director will communicate the status of your application. You may also check the status of your application any time by visiting the ISS Portal.

You can submit your application through the ISS Portal. Please view our ISS Portal Quick Reference Guide for detailed instructions on how to navigate the portal.

We require:

  • A well-written protocol and detailed line-item budget (e.g., when requesting funding) utilizing the NNI protocol and line-item budget templates. All line-item budgets will be subject to FMV analysis. The user guide can be found within the ISS Portal under Help and Training. Register/sign in here.
  • The Principal Investigator’s Curriculum Vitae (CV) - signed and dated within the last year.
  • Active medical license (e.g., if requesting study drug) is required of PI or co-PI
  • Conflict of Interest form

We support observational studies where research is measured according to standard of care, without any attempt to change or intervene. Data can be obtained through secondary use of data (e.g., claims data, medical chart review, electronic healthcare records, meta-analyses, etc.).

We support interventional drug research which processes data derived from humans or human specimens. Support of study drug must come from the NNI ISS Program.

NNI understands that ideas may arise that represent “out of the box thinking,” and are ultimately of great interest to our organization. We welcome these ideas for submission. 

Yes, please refer to the Quick Reference Guide for submission requirements and the ISS Portal Quick Reference Guide for instructions on how to access the NNI protocol and line-item budget templates.

Please submit your ISS application for the next submission deadline.

The Novo Nordisk teams strive to provide timely responses to all applications. Specific timings for review vary based on volume of protocols submitted and nature of the protocols.

For additional information on ongoing ISS please refer to our Ongoing ISS page.

Given that the Novo Nordisk Inc. (NNI) ISS Program is dedicated to building on our 100-year heritage of putting patients first, we also have a Request for Proposals (RFP) program. This program demonstrates NNI commitment to addressing evidence gaps and unmet needs to improve patient outcomes. For additional information click here.

Please refer to the Quick Reference Guide.

For additional questions, please email NNI_ISS@novonordisk.com which is monitored by the US ISS team.

For additional questions, please email NNI_ISS@novonordisk.com.